Symbiotec Pharmalab IPO Listing Details
| Listing Date | 1st September, 2026 |
| BSE Code | 544889 |
| NSE Code | SYMBIOTEC |
| ISIN Code | INE899I01028 |
| Offer Price | ₹938 to ₹988 |
| Face Value | ₹2 |
| Listing Price | ₹988 |
Symbiotec Pharmalab IPO Details
Symbiotec Pharmalab received SEBI approval for an IPO of ₹1757 crores, which comprises a ₹150 crores and offer for sale up to 1,62,65,181 equity shares with face value of ₹2 each. Symbiotec Pharmalab IPO price band is ₹938 to ₹988 per share.
How many shares did investors receive in this IPO?
- Retail minimum & maximum investors got 15 shares in 1 and 195 shares in 13 lot sizes.
- S-HNI Minimum category consisted of 210 shares in 14 lot sizes.
- S-HNI Maximum category had 1,005 shares in 67 lot sizes.
- B-HNI Minimum category received 1,020 shares in 68 lot sizes.
To invest in the Symbiotec Pharmalab IPO, each investor category has specific investment amounts:
- Retail Investors: Minimum investment of ₹14,820.
- Retail Investors: Maximum investment of ₹1,92,660.
- S-HNI Minimum: investment of ₹2,07,480.
- S-HNI Maximum: investment of ₹9,92,940.
- B-HNI Minimum: Investment of ₹10,07,760.
Symbiotec Pharmalab IPO Subscription Duration
Symbiotec Pharmalab IPO subscription started on August 24, 2026, and closed on August 27, 2026. The Symbiotec Pharmalab IPO allotment date was August 28, 2026, and the refund will be received on August 31, 2026. The Symbiotec Pharmalab IPO listing is on September 1, 2026.
- Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company.
- General Corporate Purpose.
About the Symbiotec Pharmalab IPO Company
Symbiotec Pharmalab is a pharmaceutical and biotechnology company with over 30 years of experience. It mainly manufactures Corticosteroid and Steroidal Hormone APIs, which are important ingredients used to make medicines.
The company has grown from a small laboratory-scale steroid manufacturer into a fully integrated global company. In FY2025, Symbiotec had a strong share of the global market for these APIs and was the only Indian and global company present across the top 10 categories in this market.